Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in adults aged 55 to 90 who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how these treatments may impact agitation symptoms in this population. The study is sponsored by Bristol-Myers Squibb and focuses on agitation as a complication of Alzheimers disease. Participants will be randomly assigned to receive either the combination of XanomelineTrospium Chloride Capsule and Xanomeline Enteric Capsule or a placebo. The treatments are given at specified doses on designated days. The study uses a parallel group design to compare these two options over a treatment period lasting up to 14 weeks. During the study, participants and their caregivers will attend regular visits for assessments including agitation severity using the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association total score, clinical global impressions, and other neuropsychiatric evaluations. Safety will be closely monitored through adverse event reporting and various clinical tests, including movement scales, vital signs, lab tests, ECGs, and assessments for suicidal thoughts. Caregivers will help oversee medication compliance and report on participant status. The entire study period extends through Week 18 for safety follow-up.
Actively Recruiting
Researchers are investigating the long-term safety and effectiveness of a combined drug treatment using xanomeline tartratetrospium chloride in an immediate release capsule KarXT and xanomeline enteric capsules KarX-EC for people with agitation linked to Alzheimers Disease. This study is an open-label extension of earlier studies CN012-0023 and CN012-0024. It aims to understand how well these treatments work over time and monitor any side effects. Participants who completed the previous studies will receive specified doses of KarXT and KarX-EC according to a set schedule. This phase 3 study does not include a comparison group and all participants receive the combined treatment. The treatment period lasts approximately 30 weeks, during which the effects and safety of these medications will be observed. During the study, participants will be closely monitored for any adverse events, changes in cognitive function, movement disorders, vital signs, and other health measures. Assessments include scales like the Mini-Mental State Examination MMSE, Abnormal Involuntary Movement Scale AIMS, and others related to agitation and side effects. Safety checks such as lab tests, ECGs, and questionnaires will be regularly conducted. The total study duration for participants is about 30 weeks, with follow-up to evaluate overall treatment tolerability and impact.
Actively Recruiting
Researchers are conducting a master protocol consisting of three independent, multicenter, randomized, double-blind, placebo-controlled studies to evaluate ACP-204 in adults with Alzheimers Disease Psychosis ADP. The purpose is to assess the efficacy and safety of two doses of ACP-204 compared to placebo. The studies include a Phase 2 dose-response trial followed by two Phase 3 confirmatory trials, each analyzed separately. The research addresses the treatment of psychosis symptoms in adults aged 55 to 95 years with confirmed Alzheimers disease and psychosis. Participants receive either ACP-204 at 30 mg or 60 mg doses or a matching placebo once daily, approximately at the same time each day, with or without food. Each substudy includes a screening period lasting up to 49 days, a 6-week double-blind treatment period, and a 30-day safety follow-up for those not entering an open-label extension. Vital status follow-up is also conducted for participants who end the study early. During the study, participants undergo assessments including the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales SAPS-HD and the Clinical Global Impression-Severity in the ADP context CGI-S-ADP. Study visits involve evaluation with a designated caregiver or study partner. Safety monitoring and vital status checks continue after treatment, with the total participation duration including screening, treatment, and follow-up periods.